RDHL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.10
Percentage change 1.40	%

Peers: BCRX GERN AXSM AMRN FATE ARDX LGND ACAD MNKD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.50%	Shs Outstand	1.27M	Perf Week	0.14%
Market Cap	9.17M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.27M	Perf Month	0.56%
Income	-	PEG	-	EPS next Q	-	Inst Own	5.72%	Short Float	0.44%	Perf Quarter	-34.42%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-70.09%	Short Ratio	0.28	Perf Half Y	-27.80%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-78.12%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	6.34 - 43.50	Perf YTD	-80.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-83.40%	Beta	3.66
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	163.47%	Gross Margin	-	52W Low	13.79%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	94.66%	Oper. Margin	-	RSI (14)	45.24	Volatility	8.19% 7.61%
Employees	53	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	1000.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	102.33%	Payout	0.00%	Rel Volume	0.86	Prev Close	7.12
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-90.21%	Earnings	-	Avg Volume	20.14K	Price	7.22
SMA20	-2.57%	SMA50	-7.92%	SMA200	-28.43%	Trades		Volume	8,162	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-21	Initiated	Cantor Fitzgerald	Overweight	$22
May-18-21	Initiated	H.C. Wainwright	Buy	$23
Sep-11-20	Initiated	BTIG Research	Buy
Jul-12-19	Upgrade	WBB Securities	Buy → Strong Buy
Mar-12-19	Upgrade	WBB Securities	Speculative Buy → Buy
Jan-26-18	Initiated	Nomura	Buy	$18
Oct-06-17	Initiated	Seaport Global Securities	Buy	$19
Oct-04-17	Reiterated	H.C. Wainwright	Buy	$33 → $36
Feb-24-17	Reiterated	FBR & Co.	Outperform	$36 → $25
Jul-27-16	Reiterated	FBR Capital	Outperform	$33 → $36
Sep-29-15	Initiated	Nomura	Buy
Jul-29-15	Reiterated	ROTH Capital	Buy	$30 → $31
Jun-17-15	Reiterated	H.C. Wainwright	Buy	$23 → $32
Jun-15-15	Reiterated	ROTH Capital	Buy	$27.50 → $30

Show Previous Ratings

Dec-10-24 07:00AM	Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development (PR Newswire) +8.77%
Dec-03-24 07:18AM	RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court (TipRanks) -5.74%
Dec-02-24 07:00AM	RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court (PR Newswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-28-24 07:00AM	RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND (PR Newswire)
07:29AM	Loading…
Oct-23-24 07:29AM	RedHill Biopharma and Duke Collaborate on Opaganib Development (TipRanks)
Oct-22-24 07:00AM	RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury (PR Newswire)
Oct-14-24 07:00AM	RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment (PR Newswire)
Oct-01-24 07:27AM	RedHill Biopharma Secures Opaganib COVID-19 Patent (TipRanks) -5.04%
07:00AM	RedHill and Medi-Cal Deal Maintains Talicia Reimbursement Without Prior Authorization for 15 Million Californians (PR Newswire)
Sep-30-24 07:00AM	RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 (PR Newswire)
Sep-09-24 07:00AM	RedHill's Talicia Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines (PR Newswire) +9.81%
Sep-05-24 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Sep-03-24 07:00AM	New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality (PR Newswire)
Aug-29-24 07:00AM	RedHill Biopharma Announces First Half 2024 Business Highlights (PR Newswire)
07:00AM	Loading…
Aug-26-24 07:00AM	RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma (PR Newswire) -6.54%
Aug-21-24 07:00AM	Talicia Launched in the United Arab Emirates (PR Newswire) +25.06%
Aug-19-24 07:56AM	Upcoming Stock Splits This Week (August 19 to August 23) Stay Invested (TipRanks) +10.69%
07:00AM	RedHill Announces Positive Obesity and Diabetes Results with Opaganib (PR Newswire)
Aug-16-24 07:00AM	RedHill Biopharma Announces Plan to Implement ADS Ratio Change (PR Newswire) -22.64%
Aug-01-24 07:00AM	Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease (PR Newswire) +97.87%
Jul-22-24 07:00AM	RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien (PR Newswire) +5.09%
Jul-09-24 08:00AM	RedHill Biopharma Terminates License Agreement for Aemcolo (PR Newswire)
Jun-03-24 07:00AM	RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 (PR Newswire)
May-06-24 07:43AM	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib (MT Newswires)
07:00AM	RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 (PR Newswire)
Apr-24-24 07:00AM	RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study (PR Newswire)
Apr-08-24 09:23AM	RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights (PR Newswire)
Apr-02-24 07:00AM	RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price (PR Newswire)
Mar-11-24 07:00AM	RedHill Announces New USPTO Patent Covering Talicia Through 2034 (PR Newswire)
07:00AM	Loading…
Mar-05-24 07:00AM	RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs (PR Newswire) -7.48%
Feb-20-24 07:00AM	RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication (PR Newswire)
Jan-26-24 12:46PM	RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering (PR Newswire)
Jan-25-24 09:05AM	RedHill Biopharma Announces $8 Million Registered Direct Offering (PR Newswire) -39.85%
06:00AM	RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042 (PR Newswire)
Dec-20-23 08:45AM	RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola (PR Newswire) +6.06%
Dec-12-23 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-04-23 07:00AM	RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study (PR Newswire) +13.86%
Dec-03-23 01:11PM	5 Most Volatile Stocks Under $5 For Day Trading (Insider Monkey)
Nov-30-23 09:08AM	Why Is Redhill Biopharma (RDHL) Stock Down 27% Today? (InvestorPlace) -30.56%
Nov-27-23 01:41PM	5 Investors Betting Big on RedHill Biopharma (RDHL) Stock (InvestorPlace) +216.96%
07:00AM	RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034 (PR Newswire)
Nov-14-23 08:00AM	RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market (PR Newswire) +9.00%
Oct-03-23 07:00AM	RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study (PR Newswire) -14.86%
Sep-22-23 04:15PM	RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire) -11.11%
Sep-18-23 07:00AM	RedHill Announces FDA sNDA Approval for Talicia® (PR Newswire)
Sep-05-23 07:00AM	RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) (PR Newswire)
Aug-17-23 07:00AM	RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights (PR Newswire) +13.41%
Aug-01-23 07:00AM	RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. (PR Newswire)
Jul-31-23 07:00AM	RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA (PR Newswire)
Jul-25-23 03:58PM	RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise (PR Newswire)
Jul-21-23 09:33AM	RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds (PR Newswire) -25.95%
07:00AM	RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development (PR Newswire)
Jun-12-23 08:00AM	RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights (PR Newswire)
May-22-23 07:00AM	RedHill Provides R&D Update (PR Newswire)
May-15-23 06:17PM	RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency (PR Newswire) -5.02%
May-09-23 07:00AM	RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week (PR Newswire)
May-01-23 07:00AM	RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting (PR Newswire) -8.02%
Apr-28-23 07:00AM	RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights (PR Newswire) +6.58%
Apr-17-23 07:39AM	Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet (Simply Wall St.)
Apr-11-23 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -5.76%
Apr-03-23 01:26PM	RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering (PR Newswire)
Mar-30-23 08:00AM	RedHill Biopharma Announces $6 Million Registered Direct Offering (PR Newswire) -6.33%
Mar-23-23 07:32AM	RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt (Simply Wall St.) -18.51%
Mar-21-23 07:00AM	RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders (PR Newswire)
Mar-16-23 06:15PM	RedHill Biopharma Announces Plan to Implement ADS Ratio Change (PR Newswire) -24.28%
Mar-08-23 07:05PM	RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor (PR Newswire)
Feb-28-23 08:01AM	RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development (ACCESSWIRE)
07:00AM	RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program (PR Newswire)
Feb-16-23 08:01AM	RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan (ACCESSWIRE) +6.07%
08:00AM	RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support (PR Newswire)
Feb-15-23 07:00AM	RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome (PR Newswire)
Feb-10-23 03:10PM	Raleigh pharma sheds debt in exchange for top-selling drug. Now what? (American City Business Journals)
Feb-06-23 07:00AM	RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik® (PR Newswire) +12.90%
Jan-26-23 07:00AM	RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease (PR Newswire)
Jan-03-23 11:07AM	RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study (Benzinga) +26.16%
07:00AM	RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19 (PR Newswire)
Dec-27-22 02:53PM	2022 Year in Review: Layoffs hit Triangle biotech, pharma companies (American City Business Journals) -13.06%
Dec-07-22 09:45AM	Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL) (ACCESSWIRE)
Dec-06-22 01:36PM	RedHill Biopharma Closes $8.0 Million Underwritten Public Offering (PR Newswire) -10.11%
Dec-02-22 09:00AM	RedHill Biopharma Prices $8.0 Million Underwritten Public Offering (PR Newswire) -27.21%
Dec-01-22 04:01PM	RedHill Biopharma Announces Proposed Public Offering (PR Newswire)
Nov-29-22 08:00AM	RedHill Biopharma Announces Q3/22 Results and Operational Highlights (PR Newswire) -6.13%
Nov-24-22 05:19AM	The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23% (Simply Wall St.)
Nov-17-22 08:30AM	RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury (PR Newswire)
Nov-15-22 03:09PM	RedHill Biopharma set to lose key revenue source, could 'cease operations' (American City Business Journals)
Nov-14-22 08:59AM	RedHill Says Opaganib Has Potential As Nuclear Radiation Protection For Homeland Security Countermeasures (Benzinga)
07:00AM	RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published (PR Newswire)
06:00AM	RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik® (PR Newswire)
Nov-13-22 07:33AM	RedHill Biopharma Second Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-07-22 09:49AM	RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates (PR Newswire)
Nov-04-22 07:00AM	RedHill Presents New Talicia® Data Analyses at Obesity Week 2022 (PR Newswire)
Oct-30-22 08:58AM	RedHill Biopharma Ltd.'s (NASDAQ:RDHL) Path To Profitability (Simply Wall St.)
Oct-27-22 07:45AM	After job cuts, Raleigh drugmaker considers selling lead product (American City Business Journals)
Oct-26-22 07:00AM	RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022 (PR Newswire) +6.08%
Oct-20-22 01:08PM	RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate (Zacks) -15.60%
Oct-19-22 12:34PM	RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate (Benzinga) +46.55%
07:00AM	RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent (PR Newswire)
Oct-18-22 07:00AM	RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire)
Oct-03-22 11:20AM	RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5 (Benzinga)

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Redhill Biopharma Ltd. ADR

Upgrade your FINVIZ experience